Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.02, while Zimmer Biomet Holdings Inc trades at $95.52 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMB | ZBH | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $97.74 | $107.71 |
52-Week Low | $92.95 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $94.99 with minimal daily movement (+0.16%), showing technical bearish signals from moving averages while oscillators remain neutral. The stock faces significant selling pressure with support and resistance clustered around $95. Recent corporate actions include scheduled dividend payments through mid-2026, though key financial ratios remain undisclosed in current filings.
The outlook remains cautious with technical indicators favoring sellers and limited fundamental data available. Investment opportunity centers on dividend income stream, while risks include emerging market sovereign default exposure and Federal Reserve policy sensitivity. Analyst sentiment suggests limited upside potential beyond current yield returns.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
